Kim A. Margolin MD, FASCO

Kim A. Margolin, MD, FASCO, is the medical oncology co-director of the Melanoma Program at St John's Cancer Institute in Santa Monica, CA. Her disease area of specialty is melanoma and skin cancers, and her modality area of interest is immunotherapy of all types, ranging from cytokines to cell therapies. Dr. Margolin graduated summa cum laude from UCLA and completed her medical degree as a participant in the Medical Scientist Training Program at Stanford. After internal medicine residency at Yale-New Haven Hospital, Dr. Margolin began her fellowship in hematology/oncology at the University of California, San Diego and completed the fellowship in medical oncology and hematology and bone marrow transplantation at City of Hope. She remained on the City of Hope faculty for 30 years with an interval stint as professor in medical oncology at Seattle Cancer Care Alliance (University of Washington and Fred Hutch) and a year as professor and melanoma program lead at Stanford.

Dr. Margolin has led or participated in clinical investigation of all types during her long career, starting with cytokines and small molecules and continuing with novel combinations and vaccine strategies. She has collaborated extensively intra- and extramurally and has held leadership positions in the Cytokine Working Group, the Cancer Immunotherapy Trials Network, Southwest Oncology Group, and California Cancer Consortium. She also served terms on the Oncology Drugs Advisory Committee, the American Board of Internal Medicine, and the European Organization for the Research and Treatment of Cancer as well as Melanoma Section Editor for the publication Cancer and regular grant reviewer for the Melanoma Research Alliance. Dr. Margolin is also enthusiastic about fellow education and training, and she served as the associate director of the Hematology-Oncology fellowship at the University of Washington as well as organizing a fully-revised Hematology-Oncology fellowship at City of Hope. At both institutions, she also created a clinical investigation training program for fellows and other trainees.

Dr. Margolin has served both SITC in many capacities (including two board of director terms) and has also been active in many roles with ASCO, including chair of the Cancer Education Commitee in 2010 and plenary discussant for two plenary abstracts in 2011, providing commentary on phase III studies of vemurafenib and ipilimumab, which were both approved in that year.